IFNB1 and myeloid sarcoma: Despite the persuasive clinical and experimental data on higher serum UA importance to MS risk, in randomized control trials, oral administration of an inducer of inosine ≤ 10 mg/dl, a precursor of uric acid, maintained for up to two years in combination with IFNβ, as disease-modifying treatment, did not add any additional benefit to disability accumulation compared to IFNβ alone [25,26].